News
The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled moderate to severe atopic dermatitis.
Drugs in the Pipeline
The sBLA is supported by data from the phase 3 PRIME2 and PRIME trials that assessed dupilumab in patients 18 years of age and older with prurigo nodularis.
Drugs in the Pipeline
The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma.
ATS 2022
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
ATS 2022
Does omalizumab therapy for patients with moderate to severe allergic asthma affect these patients’ use of antitussives?
ATS 2022
What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma?
Drugs in the Pipeline
The sBLA includes data from the phase 3 OSTRO study, which showed that treatment with subcutaneously administered benralizumab led to statistically significant improvements.
AAAAI 2022
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
AAAAI 2022
How does consumption of processed food by children with atopy and asthma affect the gut microbiota and disease severity?
AAAAI 2022
Is COVID-19 a serious concern for people with asthma? Study results presented at AAAAI 2022 show that this answer is not clear cut.
